Ophthalmic Viscosurgical Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Ophthalmic viscosurgical devices are sterile, injectable gels introduced into the anterior chamber of the eye during cataract phacoemulsification and other intraocular procedures. Their dual role, protecting delicate corneal endothelial cells from ultrasonic energy trauma while maintaining surgical space, makes them an indispensable consumable in modern ophthalmic surgery. The market's estimated $0.5 billion valuation in 2025 reflects the sheer scale of annual surgical volumes and the single-use nature of these products.

• •Global cataract surgeries exceed 30 million procedures per year, underpinning consistent OVD demand
• •OVDs are classified by rheological behavior into cohesive, dispersive, and combination (viscoadaptive) categories
• •No single government or statistical agency maintains a unified commercial tracking figure for this market segment

The single most powerful driver is demographic aging, which raises the global prevalence of cataract and other age-related ocular conditions, thereby increasing surgical intervention rates. Rising surgical volumes in emerging economies, expanding ophthalmology infrastructure, and growing adoption of premium intraocular lenses that require precise OVD-assisted implantation compound demand. Additionally, the clinical imperative to minimize postoperative complications such as corneal edema continues to reinforce the essential nature of these devices in standard surgical protocols.

• •Aging populations worldwide are steadily increasing cataract surgery rates across both developed and developing nations
• •Clinical studies continue to validate OVD safety profiles, sustaining physician adoption and procedural standardization
• •Expansion of surgical capacity in Asia-Pacific, Latin America, and the Middle East is opening new market access

North America currently holds the largest regional market share, supported by high surgical volumes, advanced reimbursement frameworks, and early adoption of next-generation OVD formulations. Asia-Pacific is the fastest-growing region, fueled by a large and aging population, improving healthcare access, and increasing cataract surgical rates in countries such as China and India. Europe maintains a mature but stable market, while Latin America and the Middle East represent emerging opportunities as ophthalmic surgical infrastructure continues to develop.

• •Product categories include sodium hyaluronate-based, chondroitin sulfate-based, and hybrid combination OVDs
• •Asia-Pacific is expected to register the strongest CAGR through 2030 due to demographic and infrastructure factors
• •By application, cataract surgery dominates OVD utilization, with secondary demand from corneal transplantation and glaucoma procedures

What are the recent trends and outlook?

Looking ahead, the market is expected to sustain steady growth in line with projected global cataract surgery volume increases through 2030. Sustainability is emerging as a significant consideration, with growing industry attention toward reducing the environmental footprint of single-use surgical consumables, exploring alternative biopolymer sources, and improving manufacturing processes. Innovations in OVD formulation, such as enhanced viscoadaptive agents that combine the benefits of both cohesive and dispersive types, alongside ongoing clinical research evaluating comparative device performance, are likely to drive product evolution and incremental market expansion.

• •Research into alternative, potentially more sustainable sources of glycosaminoglycans, including fungal bioproduction pathways, may reshape raw material supply chains over time
• •The trend toward outpatient and minimally invasive ophthalmic surgery supports steady OVD consumption growth in ambulatory surgical settings
• •Long-term market expansion is structurally underpinned by the combination of rising surgical volumes, clinical validation of new formulations, and incremental product innovation